Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: biotech/medical – Page 686

This groundbreaking study, which was published as the cover article in the journal Science, not only sheds light on our evolutionary history but also paves the way for a future where physicians could more accurately assess a patient’s likelihood of suffering from ailments like back pain or arthritis later in life.

“Our research is a powerful demonstration of the impact of AI in medicine, particularly when it comes to analyzing and quantifying imaging data, as well as integrating this information with health records and genetics rapidly and at large scale,” said Vagheesh Narasimhan, an assistant professor of integrative biology as well as statistics and data science, who led the multidisciplinary team of researchers, to provide the genetic map of skeletal proportions.

Read more | >

Raman spectroscopy—a chemical analysis method that shines monochromatic light onto a sample and records the scattered light that emerges—has caused frustration among biomedical researchers for more than half a century. Due to the heat generated by the light, live proteins are nearly destroyed during the optical measurements, leading to diminishing and non-reproducible results. As of recently, however, those frustrations may now be a thing of the past.

A group of researchers with the Institute for Quantum Sciences and Engineering at Texas A&M University and the Texas A&M Engineering Experiment Station (TEES) have developed a new technique that allows low-concentration and low-dose screenings of protein-to-ligand interactions in physiologically relevant conditions.

Titled thermostable-Raman-interaction-profiling (TRIP), this new approach is a paradigm-shifting answer to a long-standing problem that provides label-free, highly reproducible Raman spectroscopy measurements. The researchers published their findings in the Proceedings of the National Academy of Sciences.

Read more | >

A cutting-edge practice by two Vanderbilt researchers that enhances light in nanoscale structures could help in the detection of diseases like cancer.

The work by Justus Ndukaife, assistant professor of electrical engineering, and Sen Yang, a recent Ph.D. graduate from Ndukaife’s lab in Interdisciplinary Materials Science under Ndukaife, was published in Light: Science & Applications.

In their paper, they show how an engineered nanostructured surface—quasi-BIC dielectric metasurface—can be used to trap micro and sub-micron particles within seconds, which they say helps in the transport of analytes to biosensing surfaces. The metasurface can also serve as a sensor to detect the aggregated particles or molecules, and can be used to enhance fluorescence or Raman signals from the , thereby boosting detection sensitivity, according to the researchers.

Read more | >

Viral hepatitis is an inflammatory liver disease caused by infection with any of the known hepatitis viruses—A, B, C, D, and E. Most of the global viral hepatitis burden is from hepatitis B and C, which affect 354 million people and result in 1.1 million deaths annually. The Centers for Disease Control and Prevention estimates that in 2020 there were 14,000 and 50,300 new acute infections of hepatitis B and C in the United States, respectively, while at least 880,000 people in the country were living with chronic (long-term) hepatitis B and 2.4 million people had chronic hepatitis C. About half of those with viral hepatitis are unaware of their infection. Chronic and persistent inflammation from the disease can lead to liver failure, cirrhosis, or liver cancer. Viral hepatitis affects all ages and there are pronounced inequities in disease outcomes in the United States. Hepatitis B and C disproportionately affect people living with HIV, and HIV increases the rate of complications and death in people with viral hepatitis.

On this World Hepatitis Day, the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, shares a snapshot of its investments in basic (laboratory), preclinical (laboratory/animal), and clinical (human) research to improve screening, prevention and treatment for hepatitis B and C. Scientists in the Hepatic Pathogenesis and Structural Virology sections of NIAID’s Laboratory of Infectious Diseases conduct basic and translational research to better understand hepatitis B and C disease progression, clarify the role of hepatitis viruses in liver cancer, and inform discovery of new vaccines, medicine and technologies. Both NIAID’s Division of AIDS (DAIDS) and the Division of Microbiology and Infectious Disease (DMID) support scientific programs focused on hepatitis B and C research and curative strategies, reflecting the widespread impact of viral hepatitis and the urgent need for safe and effective interventions.

Finding a hepatitis B cure.

Read more | >